ARTL:NSD-Artelo Biosciences, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.05

Change

+0.02 (+1.94)%

Market Cap

USD 0.02B

Volume

3.06M

Avg Analyst Target

USD 7.00 (+566.67%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences has research collaboration with Trinity College Dublin to Investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was founded in 2011 and is headquartered in La Jolla, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+20.82 (+6.34%)

USD131.90B 220.17 184.41
BNTX BioNTech SE

+29.45 (+10.37%)

USD68.59B 51.85 43.53
REGN Regeneron Pharmaceuticals, Inc

+5.40 (+0.93%)

USD61.90B 16.54 12.91
VRTX Vertex Pharmaceuticals Incorpo..

-0.61 (-0.30%)

USD52.51B 19.34 13.17
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.34B 59.23 42.56
GMAB Genmab A/S

+0.69 (+1.57%)

USD28.97B 32.86 3.81
BGNE BeiGene, Ltd

+43.46 (+16.14%)

USD27.52B N/A N/A
SGEN Seagen Inc

+1.68 (+1.16%)

USD26.21B 40.30 35.56
RPRX Royalty Pharma plc

-0.67 (-1.71%)

USD23.80B 32.32 14.58
ALNY Alnylam Pharmaceuticals, Inc

+5.51 (+3.12%)

USD20.76B N/A N/A

ETFs Containing ARTL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 43.84% 85% B 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.84% 85% B 85% B
Trailing 12 Months  
Capital Gain -5.41% 50% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.41% 50% F 19% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 11.35% 47% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.35% 47% F 53% F
Risk Return Profile  
Volatility (Standard Deviation) 63.82% 49% F 28% F
Risk Adjusted Return 17.78% 45% F 34% F
Market Capitalization 0.02B 2% F 4% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.12 73% C 60% D-
Price / Cash Flow Ratio -5.69 43% F 66% D
EV/EBITDA 0.04 90% A- 98% A+
Management Effectiveness  
Return on Equity -86.88% 29% F 20% F
Return on Invested Capital -100.38% 19% F 7% F
Return on Assets -51.96% 12% F 4% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.77 49% F 34% F
Short Percent 7.30% 44% F 27% F
Beta 1.39 47% F 34% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector